1131P - Efficacy and safety of ipilimumab reinduction therapy patients with pretreated advanced melanoma participating in an Expanded Access Programme (EAP)...

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Cancer Immunology and Immunotherapy
Melanoma and other Skin Tumours
Presenter Jacopo Pigozzo
Authors J. Pigozzo1, L. Calabrò2, P.A. Ascierto3, F. De Galitiis4, P.F. Ferrucci5, P. Queirolo6, M.G. Bernengo7, M. Aglietta8, M. Mandala9, M. Del Vecchio10
  • 1U.o.oncologia Medica, Istituto Oncologico Veneto IOV-IRCCS, IT-35128 - Padova/IT
  • 2Department Of Oncology, Medical Oncology and Immunotherapy,University Hospital of Siena, Siena/IT
  • 3Unit Of Medical Oncoloty And Innovative Therapy, Istituto Nazionale Tumori Fondazione G. Pascale, Napoli/IT
  • 4Department Of Oncology, Dermopathic Institute of the Immaculate IDI-IRCCS, Rome/IT
  • 5Melanoma And Sarcoma, Istituto Europeo di Oncologia, IT-20141 - Milano/IT
  • 6National Institute For Cancer Research, San Martino Hospital, Genova/IT
  • 7Institute Of Dermatology, University Hospital St John the Baptist, Turin/IT
  • 8Div Oncologia Ed Ematologia, Fondazione Piemontese per la Ricerca sul Cancro Onlus, IT-10060 - Candiolo/IT
  • 9Oncology And Haematology, Ospedali Riuniti di Bergamo, 24100 - Bergamo/IT
  • 10Oncologia Medica, National Cancer Institute, Milan/IT

Abstract

Purpose

In the registrational phase III trial of ipilimumab, patients who progressed after initially responding to ipilimumab treatment could subsequently receive additional ipilimumab therapy with the same treatment regimen (reinduction). Here, we describe efficacy and safety data from the Italian subgroup of patients in the EAP who received reinduction with ipilimumab outside of a clinical trial setting.

Methods

Ipilimumab was available upon physician request for patients aged ≥16 years with life-threatening, unresectable stage III/IV melanoma who failed or did not tolerate previous treatments and for whom no therapeutic option was available. Induction therapy with ipilimumab was 3 mg/kg every 3 weeks for 4 doses. Patients who progressed after stable disease (SD) lasting ≥3 months or an initial partial response (PR) or complete response (CR) were eligible for reinduction therapy at the same dose/schedule. Tumour assessments were conducted at baseline and after completion of induction therapy using immune-related response criteria. Patients were monitored for adverse events (AEs), including immune-related AEs, within 3 to 4 days of each ipilimumab dose using Common Terminology Criteria for Adverse Events v.3.0.

Results

Of 848 patients participating in the EAP in Italy, 59 received reinduction treatment. After a median follow-up of 10 months, the disease control rate among 26 reinduced patients with data available was 100%; comprising nine patients with a PR and 17 with SD. Overall, only two reinduced patients died as a result of disease progression, after 11 and 13 months. As of April 2012, median overall survival for patients that received reinduction therapy had not yet been reached. In total, 57% patients reported grade 1/2 AEs. Grade 3/4 AEs were reported by 15% patients, but were only considered drug-related in one patient. AEs were generally reversible with treatment as per protocol-specific guidelines.

Conclusions

Considering available data, reinduction with ipilimumab resulted in durable objective responses and/or stable disease. No new types of toxicities occurred during reinduction and most events were mild-to-moderate.

Disclosure

P.A. Ascierto: PA has served as a consultant for Merck Sharp & Dohme, and as an advisor to Bristol-Myers Squibb (BMS), Merck Sharp & Dohme, Roche, GlaxoSmithKline, Amgen, Celgene, Medimmune and Novartis. He has received honoraria from BMS, Merck Sharp & Dohme and Roche.

P. Queirolo: Paola Queirolo has acted as an advisor for Roche, GlaxoSmithKline, Bristol-Myers Squibb and Schering-Plough and received honoraria from Bristol-Myers Squibb and Roche.

M.G. Bernengo: Maria Grazia Bernengo has acted as an advisor to Bristol-Myers Squibb, Novartis and Pfizer.

All other authors have declared no conflicts of interest.